Baillie Gifford & CO Bio N Tech Se Transaction History
Baillie Gifford & CO
- $128 Billion
- Q2 2025
A detailed history of Baillie Gifford & CO transactions in Bio N Tech Se stock. As of the latest transaction made, Baillie Gifford & CO holds 8,038,872 shares of BNTX stock, worth $892 Million. This represents 0.67% of its overall portfolio holdings.
Number of Shares
8,038,872
Previous 8,159,682
1.48%
Holding current value
$892 Million
Previous $743 Million
15.19%
% of portfolio
0.67%
Previous 0.67%
Shares
18 transactions
Others Institutions Holding BNTX
# of Institutions
317Shares Held
40.9MCall Options Held
1.37MPut Options Held
1.52M-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$470 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$444 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$399 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$210 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.51MShares$167 Million0.79% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $26.9B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...